Sun Pharma’s specialty portfolio, Organon deal to drive growth
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to...
Key Takeaways
- Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines.
- The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects.
- Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year.
Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.
Original Publisher Attribution
This summary was curated from Economic Times.